Arctic Bioscience AS (OSL:ABS)
Norway · Delayed Price · Currency is NOK 2.560
-0.440 (-14.67%)
Aug 4, 2026, 2:27 PM CET
Arctic Bioscience AS Balance Sheet
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | - | 79.6 | 144.15 | 227.36 |
Cash & Short-Term Investments | - | - | 79.6 | 144.15 | 227.36 |
Cash Growth | - | - | -44.78% | -36.60% | 1704.45% |
Accounts Receivable | 10.21 | 14.57 | 9.57 | 13.48 | 7.7 |
Other Receivables | 8.2 | 11.05 | 11.19 | 5.24 | 3.34 |
Total Trade Receivables | 18.4 | 25.62 | 20.76 | 18.71 | 11.05 |
Inventory | 29.62 | 28.99 | 32.79 | 35.46 | 28.53 |
Total Current Assets | 49.31 | 57.89 | 133.15 | 198.33 | 266.93 |
Net Property, Plant & Equipment | 22.81 | 24.47 | 26.44 | 22.33 | 15.99 |
Other Intangible Assets | 211.19 | 195.46 | 138.13 | 107.04 | 58.55 |
Goodwill | 1.34 | 1.93 | 2.53 | 0 | - |
Total Assets | 284.65 | 279.74 | 300.25 | 327.7 | 341.47 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 26.03 | 18.98 | 18.38 | 18.25 | 8.36 |
Accrued Expenses | 1.88 | 2.08 | 2.25 | 1.74 | 2.42 |
Current Portion of Long-Term Debt | 34.12 | 20.24 | 0 | - | 0 |
Other Current Liabilities | 20.94 | 26.25 | 19.02 | 20.43 | 10.13 |
Total Current Liabilities | 82.97 | 67.54 | 39.65 | 40.42 | 20.92 |
Long-Term Debt | 27.35 | 0 | 2.05 | 0 | - |
Other Long-Term Liabilities | 0.84 | 1.47 | - | - | - |
Total Long-Term Liabilities | 28.2 | 1.47 | 2.05 | 0 | - |
Total Liabilities | 111.17 | 69.01 | 41.69 | 40.42 | 20.92 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2.7 | 2.54 | 2.54 | 2.44 | 2.43 |
Additional Paid-in Capital | 170.79 | 208.19 | 256.02 | 284.84 | 318.12 |
Shareholders' Equity | 173.49 | 210.73 | 258.56 | 287.28 | 320.55 |
Total Liabilities & Equity | 284.65 | 279.74 | 300.25 | 327.7 | 341.47 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 61.48 | 20.24 | 2.05 | 0 | 0 |
Net Cash (Debt) | -61.48 | -20.24 | 77.55 | 144.15 | 227.36 |
Net Cash Growth | - | - | -46.20% | -36.60% | 5385.57% |
Net Cash Per Share | -1.98 | -0.80 | 3.05 | 5.89 | 9.34 |
Book Value | 173.49 | 210.73 | 258.56 | 287.28 | 320.55 |
Book Value Per Share | 5.58 | 8.31 | 10.17 | 11.74 | 13.17 |
Tangible Book Value | -39.04 | 13.34 | 117.9 | 180.24 | 262.01 |
Tangible Book Value Per Share | -1.26 | 0.53 | 4.64 | 7.36 | 10.77 |